SCHEMBL5266592

SCHEMBL5266592

Cn1c(CCBr)c(Cl)c(=O)n1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 2/20 0.40
MCHR1 Q99705 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.35
HCRTR1 O43613 5/20 0.34
HCRTR2 O43614 5/20 0.34
PPARD Q03181 3/20 0.34
PPARA Q07869 3/20 0.34
TRPV1 Q8NER1 1/20 0.33
TSHR P16473 1/20 0.33
LIPE Q05469 1/20 0.33
PPARG P37231 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4326943 0.90 NPBWR1 (0.41) NPBWR1MCHR1L3MBTL1POLBALDH1A1
SCHEMBL5264271 0.82 MEN1 (0.36) NPBWR1L3MBTL1ALDH1A1
SCHEMBL4319779 0.79 NPBWR1 (0.47) NPBWR1MCHR1L3MBTL1POLBALDH1A1
SCHEMBL4319898 0.79 BCHE (0.43) POLBALDH1A1CYP3A4TSHRPTGS2
SCHEMBL4332496 0.77 NPBWR1 (0.47) NPBWR1MCHR1L3MBTL1POLBALDH1A1
SCHEMBL4332003 0.74 ALDH1A1 (0.44) ALDH1A1HCRTR1HCRTR2TSHR
SCHEMBL4320317 0.73 ALDH1A1 (0.42) NPBWR1MCHR1L3MBTL1POLBALDH1A1
SCHEMBL4335745 0.73 FPR2 (0.38) NPBWR1MCHR1ALDH1A1TRPV1
SCHEMBL4329502 0.72 CHRM4 (0.48)
SCHEMBL4326359 0.72 DRD2 (0.48) ALDH1A1HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1833800-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed